TacticScaleWhat Enovis Does & How It Makes Money (ENOV)
Updated October 2026 · reflects Enovis's latest reported financials
Medical technology company making orthopedic braces, therapy devices, and joint implants. Enovis earns revenue by selling orthopedic bracing, therapy devices, and surgical implants and instruments to healthcare professionals and patients.
How Enovis makes money
Enovis earns revenue by selling orthopedic bracing, therapy devices, and surgical implants and instruments to healthcare professionals and patients. It sells through independent distributors, its own direct sales force, and directly to patients.
What Enovis does
Enovis Corporation is a medical technology company focused on musculoskeletal care, operating in the United States and internationally. Formerly known as Colfax Corporation, it was founded in 1995 and is headquartered in Wilmington, Delaware. It operates through two segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment sells orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy and compression garments, pain-management electrical stimulators, and physical therapy products. Its customers include surgeons, physical therapists, chiropractors, athletic trainers, and other clinicians. The Reconstructive segment makes implants, instruments, and enabling technologies for joint replacement of the hip, knee, shoulder, and elbow. It also covers limb reconstruction and foot, ankle, and extremity procedures. Products reach the market through independent distributors, direct sales staff, and direct-to-patient channels.
Products & services
- Rigid and soft orthopedic braces
- Hot and cold therapy systems
- Bone growth stimulators
- Electrical stimulators for pain management
- Hip, knee, and shoulder joint replacement implants
- Foot and ankle reconstruction and fixation products
What is Enovis worth?
On an owner-earnings DCF, Enovis's most-likely value is about $33 versus a recent price near $18 (84% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$15) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 15.0× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Envista (NVST) · Globus Medical (GMED) · OrthoPediatrics (KIDS) · LivaNova (LIVN) · Edwards Lifesciences (EW)